Author

Islam Elkonaissi

Observed names: I Elkonaissi, I. Elkonaissi, Islam Samir Elkonaissi

Institution: Sheikh Shakhbout Medical City

Observed institutions: Cambridge University Hospitals NHS Foundation Trust, Sheikh Shakhbout Medical City

ORCID: 0000-0002-6063-625X

Observed ORCID: 0000-0002-6063-625X

OpenAlex ID: A5059408802

CAR-T cell therapy: Efficacy in management of cancers, adverse effects, dose-limiting toxicities and long-term follow up

2024 · Mohamed Elmarasi, Islam Elkonaissi, et al. · International Immunopharmacology · 21

Smoking, Diabetes Mellitus, and Previous Cardiovascular Disease as Predictors of Anticancer Treatment-Induced Cardiotoxicity in Non–Small-Cell Lung Cancer: A Real-World Study

2023 · Hasan Kobat, Islam Elkonaissi, et al. · Clinical Lung Cancer · 17

PDF

Investigating the efficacy of osimertinib and crizotinib in phase 3 clinical trials on anti-cancer treatment-induced cardiotoxicity: are real-world studies the way forward?

2022 · Hasan Kobat, Islam Elkonaissi, et al. · Journal of Oncology Pharmacy Practice · 13

PDF

Caught in the Crossfire: Unmasking the Silent Renal Threats of Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia

2024 · Maria Benkhadra, Rola Ghasoub, et al. · Cancers · 11

PDF

Impact of antimicrobial stewardship interventions on days of therapy and guideline adherence: A comparative point-prevalence survey assessment

2023 · Jinan Shamseddine, Ahmed Sadeq, et al. · Frontiers in Tropical Diseases · 11

PDF

Current Status and Management of Chronic Myeloid Leukemia in the Gulf Region: Survey Results and Expert Opinion

2024 · Giuseppe Saglio, Mohamed Yassin, et al. · Cancers · 5

PDF

Cost-Minimization Analysis for Subcutaneous Daratumumab in the Treatment of Newly Diagnosed Multiple Myeloma in Three Gulf Countries

2024 · Anas Hamad, Shereen Elazzazy, et al. · Journal of health economics and outcomes research · 3

EE13 A Cost-Consequence Analysis of Chimeric Antigen Receptor T-Cell Therapy in Patients With Relapsed or Refractory Large B-Cell Lymphoma Across Gulf Cooperation Council Countries

2024 · S Hashmi, I Elkonaissi, et al. · Value in Health · 2

PDF

Multiple cardiotoxicities during osimertinib therapy

2023 · Hasan Kobat, Michael Davidson, et al. · Journal of Oncology Pharmacy Practice · 2

PDF

Management of COVID-19 in cancer patients receiving cardiotoxic anti-cancer therapy. Future recommendations for cardio-oncology

2021 · Hasan Kobat, Islam Elkonaissi, et al. · Oncology Reviews · 2

PDF

EE178 The Burden of Multiple Myeloma in the Gulf Region

2024 · M Farghaly, A Fasseeh, et al. · Value in Health · 1

PDF

Renal Adverse Events in Chronic Myeloid Leukemia: Can the Exposure to One TKI be the Culprit?

2024 · Reem Hajeomar, Maria Benkhadra, et al. · Blood · 1

Blastic plasmacytoid dendritic cell neoplasm: challenges in diagnosis and treatment with potential of venetoclax as an alternative to vincristine in high-risk patients—a case report

2023 · Naveed Syed, Waed Mohammad Jaber, et al. · Bulletin of the National Research Centre/Bulletin of the National Research Center · 1

PDF

EE457 Economic Burden Impact of Thyroid Eye Disease in the United Arab Emirates

2024 · H Eatamadimadi, I Elkonaissi, et al. · Value in Health

1248P Osimertinib and crizotinib cardiotoxicity: Are real-world studies the way forward?

2021 · H. Kobat, I. Elkonaissi, et al. · Annals of Oncology

Risk assessment of hyperglycaemia induced by steroid use for immunotherapy toxicity in non-small cell lung cancer (NSCLC) patients

2020 · I. Elkonaissi, M. Low, et al. · Lung Cancer

Works count: 16

Citation count: 90

H-index: 5

I10-index: 5